Urinary bladder cancer (BCa) accounts for about 7% of all new cancers in the United States with 81,190 estimated new cases and 17,240 deaths in 2018. Approximately 75% of the new diagnoses BCa will be non-muscle-invasive BCa (NMIBC) affected by recurrence and progression rates of approximately 60% and 20%, respectively. Several unmet questions have been raised in the urological community regarding BCa. In this series on BCa we collected a series of articles treating some of the most important issue for the urological community.
Bladder preservation therapy in muscle-invasive bladder cancer: Current evidence and future perspectives
The effect of perioperative blood transfusion on oncological outcomes in radical cystectomy patients: a narrative review
The impact of transurethral en bloc resection of bladder tumour on pathological and oncological outcomes
The series “Bladder Cancer” was commissioned by the editorial office, AME Medical Journal without any sponsorship or funding. Marco Moschini served as the unpaid Guest Editor for the series.